FDA Clearance Tracker · P190032-S029
FoundationOne Liquid CDx
Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this decision)Source: openFDAMethods & limitations
Decided
May 27, 2026
Approved
Time to decision
490 days
Received Jan 22, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P190032-S029
- Device name
- FoundationOne Liquid CDx
- Applicant
- Foundation Medicine, Inc.
- Applicant location
- Boston, MA
- Received
- Jan 22, 2025
- Decided
- May 27, 2026
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P190032
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval order to expand the intended use of FoundationOne Liquid CDx (F1LCDx) to include a companion diagnostic indication for the detection of HRR gene alterations (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C) in patients with metastatic castrate-resistant prostate cancer (mCRPC) who may benefit from treatment with TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide).
Source documents
Other decisions for Foundation Medicine, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- FoundationOne CDx (F1CDx)PMA supplement
P170019-S060 · Decided May 27, 2026 · 614 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.